Tapewire

Nasdaq · USD

INSM

INSMED Inc

Export transactions ↓
Tapewire entity
3174
SEC CIK
0001104506
Parsed reports
490

Last 12 months

Inside the activity.

0 purchase rows · 169 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025023
Dec 2025018
Jan 2026044
Feb 2026022
Mar 202608
Apr 2026010
May 2026019
Jun 2026013
Jul 202607
Aug 202604
Sep 202601
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 6,830 $10.85 $74,105.50
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 6

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 240,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 6,768 $78.44 $530,881.92
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 5

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,534

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 6,768 shares sold at prices ranging from $78.31 to $78.80 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 9,869 $77.97 $769,485.93
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 386,302

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 9,869 shares sold at prices ranging from $77.29 to $78.28 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 1,872 $76.35 $142,927.20
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 396,171

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 1,872 shares sold at prices ranging from $76.00 to $76.57 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 241 $75.25 $18,135.25
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 398,043

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 241 shares sold at prices ranging from $74.86 to $75.83 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:44 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 18,750 $22.76 $426,750.00
Disclosure

SEC source: 0001628280-25-004076 · wk-form4_1738791860.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 398,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:33 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
Exercise / conversionStock Option (right to buy) · Derivative 41,140 $0.00 Strike: $13.67 $0.00
Disclosure

SEC source: 0001628280-25-003322 · wk-form4_1738359228.xml · derivative · entry 5

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 41,140 shares

Expires 2027-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:33 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
Exercise / conversionStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $16.16 $0.00
Disclosure

SEC source: 0001628280-25-003322 · wk-form4_1738359228.xml · derivative · entry 4

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2026-01-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:33 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
SaleCommon Stock 91,140 $80.00 $7,291,200.00
Disclosure

SEC source: 0001628280-25-003322 · wk-form4_1738359228.xml · nonDerivative · entry 3

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,083

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:33 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
Exercise / conversionCommon Stock 41,140 $13.67 $562,383.80
Disclosure

SEC source: 0001628280-25-003322 · wk-form4_1738359228.xml · nonDerivative · entry 2

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 30, 2025 Filed Jan 31, 2025 21:33 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
Exercise / conversionCommon Stock 50,000 $16.16 $808,000.00
Disclosure

SEC source: 0001628280-25-003322 · wk-form4_1738359228.xml · nonDerivative · entry 1

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,083

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 6,830 $0.00 Strike: $10.85 $0.00
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · derivative · entry 11

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 218,630

Underlying: Common Stock · 6,830 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 18,750 $0.00 Strike: $22.76 $0.00
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · derivative · entry 10

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 18,750 shares

Expires 2025-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 631 $71.01 $44,807.31
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 8

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 233,924

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: This is the weighted average sales price representing 631 shares sold at prices ranging from $70.92 to $71.23 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 4,700 $70.31 $330,457.00
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 7

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 234,555

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: This is the weighted average sales price representing 4,700 shares sold at prices ranging from $69.91 to $70.90 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 1,499 $69.40 $104,030.60
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 6

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 239,255

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 1,499 shares sold at prices ranging from $68.87 to $69.87 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 6,830 $10.85 $74,105.50
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 5

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Indirect · By the Katie Procter Dynasty Trust

Disclosed balance after: 240,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 2,473 $71.05 $175,706.65
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 379,534

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 2,473 shares sold at prices ranging from $70.89 to $71.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 22,696 $70.32 $1,595,982.72
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 382,007

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 22,696 shares sold at prices ranging from $69.89 to $70.89 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 6,636 $69.39 $460,472.04
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 404,703

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 6,636 shares sold at prices ranging from $68.87 to $69.86 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 15, 2025 Filed Jan 16, 2025 21:37 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 18,750 $22.76 $426,750.00
Disclosure

SEC source: 0001628280-25-001732 · wk-form4_1737063445.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 411,339

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 14, 2025 Filed Jan 16, 2025 21:38 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 1,384 $68.72 $95,108.48
Disclosure

SEC source: 0001628280-25-001736 · wk-form4_1737063475.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,165

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 14, 2025 Filed Jan 16, 2025 21:37 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 1,457 $68.72 $100,125.04
Disclosure

SEC source: 0001628280-25-001735 · wk-form4_1737063465.xml · nonDerivative · entry 1

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,082

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 14, 2025 Filed Jan 16, 2025 21:37 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
SaleCommon Stock 872 $68.72 $59,923.84
Disclosure

SEC source: 0001628280-25-001733 · wk-form4_1737063455.xml · nonDerivative · entry 1

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,083

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 4,801 $63.62 $305,439.62
Disclosure

SEC source: 0001628280-25-001207 · wk-form4_1736552729.xml · nonDerivative · entry 5

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,549

F6 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 1,371 $63.73 $87,373.83
Disclosure

SEC source: 0001628280-25-001207 · wk-form4_1736552729.xml · nonDerivative · entry 4

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,350

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Bonstein SaraChief Financial Officer
SaleCommon Stock 1,066 $63.72 $67,925.52
Disclosure

SEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 4

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,863

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
SaleCommon Stock 3,092 $63.62 $196,713.04
Disclosure

SEC source: 0001628280-25-001205 · wk-form4_1736552710.xml · nonDerivative · entry 5

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,955

F6 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
SaleCommon Stock 965 $63.87 $61,634.55
Disclosure

SEC source: 0001628280-25-001205 · wk-form4_1736552710.xml · nonDerivative · entry 4

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,047

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:45 UTC
Wise John DraytonChief Commercial Officer
SaleCommon Stock 287 $65.40 $18,769.80
Disclosure

SEC source: 0001628280-25-001204 · wk-form4_1736552700.xml · nonDerivative · entry 6

Wise John Drayton · CIK 0001930805 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,562

F3 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 2,978 $63.36 $188,686.08
Disclosure

SEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 392,589

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC
Smith Michael AlexanderChief Legal Officer
SaleCommon Stock 319 $63.38 $20,218.22
Disclosure

SEC source: 0001628280-25-001202 · wk-form4_1736552679.xml · nonDerivative · entry 4

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,965

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 3,604 $63.62 $229,286.48
Disclosure

SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 5

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 147,539

F6 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 10, 2025 Filed Jan 10, 2025 23:44 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 1,298 $63.86 $82,890.28
Disclosure

SEC source: 0001628280-25-001201 · wk-form4_1736552668.xml · nonDerivative · entry 4

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,143

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Flammer Martina M.D.Chief Medical Officer
GrantStock Option (right to buy) · Derivative 31,930 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001207 · wk-form4_1736552729.xml · derivative · entry 6

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,930

Underlying: Common Stock · 31,930 shares

Expires 2035-01-08

F7 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Flammer Martina M.D.Chief Medical Officer
GrantCommon Stock 6,657 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-001207 · wk-form4_1736552729.xml · nonDerivative · entry 3

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,721

F4 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F5 · price: Each RSU was granted on January 8, 2025 for no consideration.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 1,702 $66.16 $112,604.32
Disclosure

SEC source: 0001628280-25-001207 · wk-form4_1736552729.xml · nonDerivative · entry 2

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,064

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Bonstein SaraChief Financial Officer
GrantStock Option (right to buy) · Derivative 31,930 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · derivative · entry 5

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,930

Underlying: Common Stock · 31,930 shares

Expires 2035-01-08

F6 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Bonstein SaraChief Financial Officer
GrantCommon Stock 6,657 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 3

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,929

F4 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F5 · price: Each RSU was granted on January 8, 2025 for no consideration.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Bonstein SaraChief Financial Officer
SaleCommon Stock 1,464 $66.05 $96,697.20
Disclosure

SEC source: 0001628280-25-001206 · wk-form4_1736552720.xml · nonDerivative · entry 2

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,272

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
GrantStock Option (right to buy) · Derivative 27,370 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001205 · wk-form4_1736552710.xml · derivative · entry 6

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,370

Underlying: Common Stock · 27,370 shares

Expires 2035-01-08

F7 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
GrantCommon Stock 5,706 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-001205 · wk-form4_1736552710.xml · nonDerivative · entry 3

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,012

F4 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F5 · price: Each RSU was granted on January 8, 2025 for no consideration.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Schaeffer Orlov S NicoleChief People Strategy Officer
SaleCommon Stock 1,209 $65.84 $79,600.56
Disclosure

SEC source: 0001628280-25-001205 · wk-form4_1736552710.xml · nonDerivative · entry 2

Schaeffer Orlov S Nicole · CIK 0001401017 · Chief People Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 96,306

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Wise John DraytonChief Commercial Officer
GrantStock Option (right to buy) · Derivative 31,930 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001204 · wk-form4_1736552700.xml · derivative · entry 8

Wise John Drayton · CIK 0001930805 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,930

Underlying: Common Stock · 31,930 shares

Expires 2035-01-08

F8 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Wise John DraytonChief Commercial Officer
GrantCommon Stock 6,657 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-001204 · wk-form4_1736552700.xml · nonDerivative · entry 5

Wise John Drayton · CIK 0001930805 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,849

F5 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F6 · price: Each RSU was granted on January 8, 2025 for no consideration.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:45 UTC
Wise John DraytonChief Commercial Officer
SaleCommon Stock 392 $66.21 $25,954.32
Disclosure

SEC source: 0001628280-25-001204 · wk-form4_1736552700.xml · nonDerivative · entry 4

Wise John Drayton · CIK 0001930805 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,192

F3 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC
Lewis WilliamDirector · Chair and CEO
GrantStock Option (right to buy) · Derivative 109,490 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · derivative · entry 7

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,490

Underlying: Common Stock · 109,490 shares

Expires 2035-01-08

F5 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC
Lewis WilliamDirector · Chair and CEO
GrantCommon Stock 22,824 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 395,567

F3 · shares: Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.

F4 · price: Each RSU was granted on January 8, 2025 for no consideration.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 3,999 $65.96 $263,774.04
Disclosure

SEC source: 0001628280-25-001203 · wk-form4_1736552690.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 372,743

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 23:44 UTC
Smith Michael AlexanderChief Legal Officer
GrantStock Option (right to buy) · Derivative 27,370 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001628280-25-001202 · wk-form4_1736552679.xml · derivative · entry 5

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,370

Underlying: Common Stock · 27,370 shares

Expires 2035-01-08

F6 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.